.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
SYGMA 1 compared as-needed budesonide-formoterol, daily maintenance budesonide plus as-needed reliever, and as-needed terbutaline in patients with mild asthma. The trial showed that as-needed budesonide-formoterol provided better symptom control than terbutaline alone and substantially reduced the rate of severe exacerbations compared with the beta-agonist-only strategy. Its exacerbation protection was broadly similar to daily budesonide, while total inhaled glucocorticoid exposure was considerably lower. The study is important because it challenged the assumption that patients with mild asthma must use a fixed daily inhaled corticosteroid schedule to obtain meaningful protection from severe exacerbations. At the same time, as-needed therapy was not equivalent to maintenance budesonide for symptom control. For practicing HCPs, this distinction is critical: the appropriate reliever/controller strategy depends on the clinical phenotype, symptom pattern and goals of treatment. The findings fit the NAPCON allergy and airway track, particularly its emphasis on phenotyping and practical inhaler decisions. The study should be discussed alongside modern asthma strategy rather than used to justify intermittent treatment without an anti-inflammatory component.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
SYGMA 1 compared as-needed budesonide-formoterol, daily maintenance budesonide plus as-needed reliever, and as-needed terbutaline in patients with mild asthma. The trial showed that as-needed budesonide-formoterol provided better symptom control than terbutaline alone and substantially reduced the rate of severe exacerbations compared with the beta-agonist-only strategy. Its exacerbation protection was broadly similar to daily budesonide, while total inhaled glucocorticoid exposure was considerably lower. The study is important because it challenged the assumption that patients with mild asthma must use a fixed daily inhaled corticosteroid schedule to obtain meaningful protection from severe exacerbations. At the same time, as-needed therapy was not equivalent to maintenance budesonide for symptom control. For practicing HCPs, this distinction is critical: the appropriate reliever/controller strategy depends on the clinical phenotype, symptom pattern and goals of treatment. The findings fit the NAPCON allergy and airway track, particularly its emphasis on phenotyping and practical inhaler decisions. The study should be discussed alongside modern asthma strategy rather than used to justify intermittent treatment without an anti-inflammatory component.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
